newsfilter
← Latest News
GlobeNewswire·

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

Reporting Complete Response Data from the Ongoing APTIVATE International Phase 1/2 Study of Tuspetinib (TUS) in Relapsed/Refractory AML PatientsTUS Single Agent and TUS/VEN Combination Demonstrate Favorable Safety and